Parkwood LLC Raises Holdings in AstraZeneca PLC (NASDAQ:AZN)

Parkwood LLC lifted its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 62.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 118,199 shares of the company's stock after purchasing an additional 45,514 shares during the quarter. Parkwood LLC's holdings in AstraZeneca were worth $7,744,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the business. Banque Transatlantique SA purchased a new stake in AstraZeneca in the fourth quarter worth approximately $26,000. Albion Financial Group UT lifted its holdings in shares of AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company's stock valued at $40,000 after buying an additional 248 shares during the period. CoreCap Advisors LLC lifted its holdings in shares of AstraZeneca by 31.8% during the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock valued at $42,000 after buying an additional 155 shares during the period. Golden State Wealth Management LLC purchased a new position in shares of AstraZeneca in the 4th quarter worth $55,000. Finally, Crews Bank & Trust bought a new stake in shares of AstraZeneca in the fourth quarter worth $55,000. Hedge funds and other institutional investors own 20.35% of the company's stock.

AstraZeneca Price Performance

NASDAQ AZN opened at $67.72 on Wednesday. The business's fifty day moving average is $70.96 and its 200 day moving average is $69.60. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $87.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. The company has a market capitalization of $210.02 billion, a PE ratio of 29.96, a price-to-earnings-growth ratio of 1.42 and a beta of 0.40.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. The firm had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The business's quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.06 EPS. Sell-side analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AZN. Morgan Stanley began coverage on AstraZeneca in a research report on Wednesday, February 12th. They set an "overweight" rating for the company. BNP Paribas started coverage on AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target for the company. Finally, UBS Group upgraded shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, AstraZeneca has a consensus rating of "Buy" and a consensus price target of $88.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.